Streetbeat News

Regulatory

NVO

A study reveals that the real-world effectiveness of GLP-1 agonists like Novo Nordisk's Ozempic and Wegovy is lower than clinical trials suggest. Despite high demand and FDA approvals for expanded use, patients experience less weight loss in practice, with high discontinuation rates.

Portfolio Pulse from Vandana Singh

October 03, 2024 | 3:27 pm

BILI

Bilibili Inc (NASDAQ:BILI) shares fell 9.44% after a 90% surge, driven by optimism over China's stimulus measures. The decline is linked to geopolitical tensions in the Middle East affecting investor sentiment. Bilibili, a major Chinese video-sharing platform, faces challenges from market volatility and regulatory pressures.

Portfolio Pulse from Henry Khederian

October 03, 2024 | 3:15 pm

CVS

LLY

Texas Attorney General Ken Paxton has filed a lawsuit against major insulin manufacturers and pharmacy benefit managers, including Eli Lilly, Express Scripts, and CVS Pharmacy, accusing them of conspiring to inflate insulin prices. The lawsuit claims these companies violated the Texas Deceptive Trade Practices Act by artificially raising insulin prices and engaging in unlawful civil conspiracy.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 3:14 pm

RBLX

The Bear Cave has released its fourth report on Roblox, titled 'Problems at Roblox (RBLX) #4'. This report may highlight issues or concerns regarding Roblox's operations or financials.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 3:07 pm

SPY

The IMF suggests that the U.S. Federal Reserve should maintain a data-dependent and meeting-by-meeting approach to monetary policy easing. This indicates a cautious and flexible strategy in response to economic conditions.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 3:02 pm

MLSS

Milestone Scientific Inc. (NYSE:MLSS) has announced the commercial rollout of its CompuFlo Epidural System at iHeal Pain Center, following successful procedures and a favorable Medicare price assignment. This marks a significant step in their commercial activities, supported by a strategic partnership with Axial Biologics.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 3:02 pm

EWJ

The IMF acknowledges the Bank of Japan's efforts to normalize monetary policy, aiming to stabilize inflation at a 2% target. The BOJ is advised to continue data-driven rate increases. Japan's fiscal policy should focus on growth-friendly consolidation to ensure debt sustainability.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 3:02 pm

SLM

SOFI

SPY

The Biden administration's student loan forgiveness plan is allowed to proceed temporarily, which could impact companies involved in student loans and broader market indices.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 3:00 pm

GLD

QQQ

SPY

TLT

UUP

The U.S. services sector showed strong growth in September, with the Services PMI reaching 54.9%, its highest since February 2023. This raises questions about the Federal Reserve's upcoming rate cut decision. The S&P 500, Nasdaq 100, and long-dated Treasuries saw declines, while the U.S. dollar index rose.

Portfolio Pulse from Michael Cohen

October 03, 2024 | 2:54 pm

BMY

The FDA has approved the use of nivolumab as a neoadjuvant and adjuvant treatment for resectable non-small cell lung cancer. This approval is significant for Bristol-Myers Squibb (BMY), the company behind nivolumab, as it expands the drug's market potential.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 2:52 pm